Evidence map›Paper›PMID 34959307›Full record

ArticlePharmaceutics2021

PEG-Modified

Desislava Budurova, Denitsa Momekova, Georgi Momekov, Pavletta Shestakova, Hristo Penchev, Stanislav Rangelov

Abstract read
In one paragraph

Article in Pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Desislava BudurovaInstitute of Polymers, Bulgarian Academy of Sciences, 103 Acad. Georgi Bonchev St., 1113 Sofia, Bulgaria.ORCID 0000-0002-3853-3625
Denitsa MomekovaDepartment of Pharmaceutical Technology and Biopharmaceutics, Faculty of Pharmacy, Medical University-Sofia, 2 Dunav St., 1000 Sofia, Bulgaria.
Georgi MomekovDepartment of Pharmacology, Pharmacotherapy and Toxicology, Faculty of Pharmacy, Medical University-Sofia, 2 Dunav St., 1000 Sofia, Bulgaria.
Pavletta ShestakovaInstitute of Organic Chemistry with Centre of Phytochemistry, Bulgarian Academy of Sciences, Acad. Georgi Bonchev St. Bldg 9, 1113 Sofia, Bulgaria.
Hristo PenchevInstitute of Polymers, Bulgarian Academy of Sciences, 103 Acad. Georgi Bonchev St., 1113 Sofia, Bulgaria.
Stanislav RangelovInstitute of Polymers, Bulgarian Academy of Sciences, 103 Acad. Georgi Bonchev St., 1113 Sofia, Bulgaria.

Funding

Bulgarian Ministry of Education and Science D01-217/30.11.2018
6 · The paper itself

Abstract

The hepatoprotective properties of silibinin, as well its therapeutic potential as an anticancer and chemo-preventive agent, have failed to progress towards clinical development and commercialization due to this material's unfavorable pharmacokinetics and physicochemical properties, low aqueous solubility, and chemical instability. The present contribution is focused on the feasibility of using PEGylated calixarene, in particular polyoxyethylene-derivatized

Indexed as

calix[8]arenescytotoxicityinclusion complexesPEGylationsilibinin

Identifiers

PMID34959307
PMCPMC8709077

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.